Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders

Gary A. Ulaner, C. Ola Landgren

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations

Abstract

Fluorine-18 (18F)-fluorodeoxyglucose (FDG) positron emission tomography (PET) allows evaluation of elevated glucose metabolism in malignancies. There has been increasing interest in FDG PET/CT for plasma cell disorders since the International Myeloma Working Group outlined multiple applications of this imaging modality, including distinguishing smoldering myeloma from active multiple myeloma, confirmation of solitary plasmacytoma, and multiple indications in patients with known multiple myeloma, including determining extent of initial disease, monitoring therapy response, and detection of residual disease following therapy. The field of molecular imaging is now shifting focus from evaluation of metabolism to targeted evaluation of specific tumor markers. Targeted PET imaging targeted of CXCR4 and CD38 has advanced into translational clinical trials, bringing us closer to powerful imaging options for myeloma. In this review we discuss the current applications of FDG PET/CT in plasma cell disorders, as well as advances in targeted PET imaging.

Original languageEnglish (US)
Article number101148
JournalBest Practice and Research: Clinical Haematology
Volume33
Issue number1
DOIs
StatePublished - Mar 2020
Externally publishedYes

Keywords

  • 18F-fluorodeoxyglucose (FDG)
  • Multiple myeloma
  • Positron emission tomography (PET)
  • immunoPET

ASJC Scopus subject areas

  • Oncology
  • Clinical Biochemistry

Fingerprint

Dive into the research topics of 'Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders'. Together they form a unique fingerprint.

Cite this